CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). It is associated with local activation of microglia and astroglia, infiltration of activated macrophages and T cells, active degradation of myelin and damage to axons and neurons. The proposed role for CX 3 CL1 (fractalkine) in the control of microglia activation and leukocyte infiltration places this chemokine and its receptor CX 3 CR1 in a potentially strategic position to control key aspects in the pathological events that are associated with development of brain lesions in MS. In this study, we examine this hypothesis by analyzing the distribution, kinetics, regulation and cellular origin of CX 3 CL1 and CX 3 CR1 mRNA expression in the CNS of rats with an experimentally induced MS-like disease, myelin oligodendrocyte glycoprotein (MOG)-induced autoimmune encephalomyelitis (EAE). Methods: The expression of CX 3 CL1 and its receptor CX 3 CR1 was studied with in situ hybridization histochemical detection of their mRNA with radio labeled cRNA probes in combination with immunohistochemical staining of phenotypic cell markers. Both healthy rat brains and brains from rats with MOG EAE were analyzed. In defined lesional stages of MOG EAE, the number of CX 3 CR1 mRNA-expressing cells and the intensity of the in situ hybridization signal were determined by image analysis. Data were statistically evaluated by ANOVA, followed by Tukey\primes multiple comparison test. Results: Expression of CX 3 CL1 mRNA was present within neuronal-like cells located throughout the neuraxis of the healthy rat. Expression of CX 3 CL1 remained unaltered in the CNS of rats with MOG-induced EAE, with the exception of an induced expression in astrocytes within inflammatory lesions. Notably, the brain vasculature of healthy and encephalitic animals did not exhibit signs of CX 3 CL1 mRNA expression. The receptor, CX 3 CR1, was expressed by microglial cells in all regions of the healthy brain. Induction of MOG-induced EAE was associated with a distinct accumulation of CX 3 CR1 mRNA expressing cells within the inflammatory brain lesions, the great majority of which stained positive for markers of the microglia-macrophage lineage. Analysis in time-staged brain lesions revealed elevated levels of CX 3 CR1 mRNA in microglia in the periplaque zone, as well as a dramatically enhanced accumulation of CX 3 CR1 expressing cells within the early-active, late-active and inactive, demyelinated lesions. Conclusion: Our data demonstrate constitutive and regulated expression of the chemokine CX 3 CL1 and its receptor CX 3 CR1 by neurons/astrocytes and microglia, respectively, within the normal and inflamed rat brain. Our findings propose a mechanism by which neurons and reactive astrocytes may control migration and function of the surrounding microglia. In addition, the accumulation of CX 3 CR1 expressing cells other than microglia within the inflammatory brain lesions indicate a possible role for CX 3 CL1 in controlling invasion of peripheral leucocytes to the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jung, S., Aliberti, J., Graemmel, P., Sunshine, M. J., Kreutzberg, G. W., Sher, A., & Littman, D. R. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.4106-4114.2000 · Cited by 2,632 · cited 2×
“These cells may be speculated to correspond to infiltrating blood leukocytes, such as NK cells, γδ T cells and/or terminally differentiated CD4+ and CD8+ T cells, which previously have been described to express CX3CL1 receptors and/or to respond functionally upon CX3CL1 stimulation [14,15,33,52, 53 ].”
BackgroundNeuN, a neuronal specific nuclear protein in vertebratesxs
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992) · Development · doi:10.1242/dev.116.1.201 · Cited by 2,351
A new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013 · cited 3×
“CX3CL1 (alternative names: fractalkine or neurotactin) was identified in 1997 as a chemokine of 373 amino acids with, for the chemokine family, an atypical structure, a chemokine domain tethered on top of a mucin-like domain which is followed by a single transmembrane spanning domain and a short cytoplasmic tail [2-4].”
BackgroundResultDecreased atherosclerosis in CX3CR1–/– mice reveals a role for fractalkine in atherogenesis
Lesnik, P., Haskell, C. A., & Charo, I. F. (2003) · Journal of Clinical Investigation · doi:10.1172/jci15555 · Cited by 487 · cited 2×
“Interestingly, concurrent studies have provided functional evidences that CX3CR1 and its ligand serve as important mediators of inflammation and pathology in animal models models for atherosclerosis, transplant rejections, glomerulonephritis and stroke [12,19,29,59].”
BackgroundExpression of CX 3 CR1 chemokine receptors on neurons and their role in neuronal survival
Meucci, O., Fatatis, A., Simen, A. A., & Miller, R. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090017497 · Cited by 385 · cited 1×
“This contrasts to earlier findings of CX3CR1-like immunoreactivity within neurons of a rat model for prion disease [22], in humans with HIV encephalitis [44] and in vitro cultivated hippocampal neurons [54].”
ResultHughes, P. M., Botham, M. S., Frentzel, S., Mir, A., & Perry, V. H. (2002) · Glia · doi:10.1002/glia.10037 · Cited by 252
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury
Soriano, S. G., Amaravadi, L. S., Wang, Y. F., Zhou, H., Yu, G. X., Tonra, J. R., Fairchild-Huntress, V., Fang, Q., Dunmore, J. H., Huszar, D., et al. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(02)00033-4 · Cited by 222
Zujovic, V., Schussler, N., Jourdain, D., Duverger, D., & Taupin, V. (2001) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00259-4 · Cited by 102
Cited by
Microglial M1/M2 polarization and metabolic states
Orihuela, R., McPherson, C. A., & Harry, G. J. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13139 · Cited by 2,070
“TARGETS Enzymesa Akt AMPK Arg-1, arginase 1 Caspase-1 Histone demethylase HK, hexokinase iNOS PI3K GPCRsb CCR2 Catalytic receptorsc NLRC4 (IPAF) NLRP1 NLRP3 TLR LIGANDS CCL2 IL-6 CCL17 IL-10 CCL20 IL-13 CCL22 IL-18 CCL24 Il-21 CX3CL1 IL-23 CXCL13 IL-33 IFN-γ LPS IL-1β NO IL-3 TGF-β IL-4 TNF-α These Tables list key pro…”
BackgroundInfluentialMicroglia during development and aging
Harry, G. J. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.04.013 · Cited by 524
Jurcau, A., & Simion, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010014 · Cited by 500
Zlotnik, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.22024 · Cited by 421
Chemokines and Chemokine Receptors: Standing at the Crossroads of Immunobiology and Neurobiology
Ransohoff, R. M. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.010 · Cited by 371
Metadata
- Authors
- Sunnemark, D., Eltayeb, S., Nilsson, M., Wallström, E., Lassmann, H., Olsson, T., Berg, A.-L., & Ericsson-Dahlstrand, A.
- Venue
- Journal of Neuroinflammation
- Published
- 2005-07-29
- Volume
- 2
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W2031703541
- Cited by
- 124
- References
- 8
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. https://app.cochat.ai/papers/10.1186/1742-2094-2-17
- The paper
- Sunnemark, D., Eltayeb, S., Nilsson, M., Wallström, E., Lassmann, H., Olsson, T., Berg, A.-L., & Ericsson-Dahlstrand, A. (2005). CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin. Journal of Neuroinflammation. https://doi.org/10.1186/1742-2094-2-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.